FDA published two final guidance documents related to food allergens: Questions and Answers Regarding Food Allergens, ...
C&EN’s tabulation follows approvals from the FDA’s Center for Drug Evaluation and Research; therefore, it does not include blood products, gene therapies, vaccines, and other therapies that ...
BENGALURU: IT services company Infosys on Thursday posted a 11.4% growth in net profit at Rs 6,806 crore for the ... the company has raised its revenue guidance from 3.75%- 4.5% to 4.5%-5.0% ...
Infosys reported an 11.46% rise in net profit to Rs 6,806 crore for the December quarter FY25, driven by growth in financial services and manufacturing. Revenue growth boosts its FY25 guidance to ...
New Delhi, Jan 16 (PTI) IT services major Infosys on Thursday reported 11.46 per cent increase in consolidated net profit at Rs 6,806 crore for December quarter FY25 and raised its guidance on the ...
Infosys Q3 Results: The Bengaluru-based tech giant also revised its revenue guidance for the current fiscal year upward to 4.5%-5%, signaling optimism in its growth ...
The U.S. Food and Drug Administration (FDA) banned the use of Red Dye No. 3 in food and ingested drugs on Wednesday, more than three decades after the agency prohibited it from being used in ...
Tech giant, Infosys has reported consolidated net profit of Rs 6,806 crore in Q3 of FY25 ... Infosys announced revenue growth guidance of 4.5%-5.0% in constant currency. While Operating margin ...
Food and Drug Administration officials granted a 2022 petition filed by two dozen food safety and health advocates, who urged the agency to revoke authorization for the substance that gives some ...
said in a statement following Wednesday’s announcement that they will “continue to follow and comply with FDA’s guidance and safety standards”. “Our consumers and everyone in the food ...
Share on Pinterest Red dye No. 3 has been shown in animal studies to cause cancer. JurgaR/Getty Images The FDA issued a ban on the use of red dye No. 3 in food and beverage products as well as ...